.svg){kind=small}
Market Insights Snapshot
In August 2026, Amend Cannabis concentrated 66.70% of sales in Topical, up 40.36% month over month, while Tincture & Sublingual fell to 33.30% share with a 25.44% month-over-month decline; average prices split at $36.47 for Topical versus $38.91 for Tincture & Sublingual. This mix shift coexists with a 24-month sales contraction of 73.77% and a null reported year-over-year rate, indicating the brand is leaning into Topical volume recovery while pulling back in Tincture & Sublingual to stabilize margins and simplify assortment in Missouri.
The directional skew toward Topical (+40.36% MoM) alongside a concurrent Tincture & Sublingual pullback (−25.44% MoM) implies a deliberate reallocation toward a lower-priced but higher-velocity lane at $36.47 versus $38.91, aiming to rebuild baseline throughput after a 73.77% 24‑month decline. Given the brand’s Topical category leadership within its own mix at 66.70% share and the absence of a reported Topical rank in Missouri, the pattern suggests a positioning pivot toward depth in a single category to improve shelf efficiency and price ladder clarity rather than breadth across categories.
Competitive Landscape
Amend Cannabis sits at rank #8 in August 2026 in MO Topical, down one spot from #7 in May 2026 and four spots off its peak at #4 in August 2024; with no year-over-year rank reported, the three-month slippage from #7 to #8 contrasts with Mary's Medicinals holding #1 year-over-year and Escape Artists retaining #2 despite a 41.4% YoY sales decline. The competitive middle tightened as Drool moved from #5 YoY to #4 and Vlasic Labs advanced from #6 YoY to #5, meaning Amend Cannabis now trails brands that gained 1–2 rank positions while it lost one in three months; this trajectory implies that without a share-capturing move, Amend Cannabis risks drifting from a prior peak-tier position toward the lower half of the top 10.
Notable Products
CBD/THC 1:1 Amend Infused Balm (500mg CBD, 500mg THC) posted the standout move with a 93.8% month-over-month gain while sitting at rank 5, and CBD/THC 1:1 Amend Tincture (100mg CBD, 100mg THC, 30ml) plunged 46.8% to rank 4, signaling a sharp redistribution of shopper interest. The flagship CBD/THC 1:1 Amend Infused Balm (250mg CBD, 250mg THC) in rank 1 grew 7.9% while the CBD/THC 1:1 Amend Tincture (400mg CBD, 400mg THC) in rank 2 slipped 6.1%, and three of the top five are Topical SKUs, concentrating demand in non-ingestible formats; this pattern points to a pivot toward higher-potency balms and away from lower-dose tinctures. Only one product crossed the $5,000 mark, reinforcing that gains are driven by share shifts rather than a broad revenue tide.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
